Medications Do Not Necessarily Normalize Cognition in ADHD Patients
C. Thomas Gualtieri M.D.*
and
Lynda G. Johnson Ph.D.
North Carolina Neuropsychiatry Clinics
* To whom correspondence should be addressed. E-mail: tg{at}ncneuropsych.com.
 |
Abstract |
|---|
Objective: Although ADHD medications are effective for the behavioral components of the disorder, little information exists concerning their effects on cognition, especially in community samples. Method: A cross-sectional study of ADHD patients treated with three different ADHD drugs was conducted. Patients’ performance on a computerized neurocognitive screening battery was compared to untreated ADHD patients and normal controls (NML). A total of 177 ADHD patients aged 10 to 18, achieved a favorable response to one of the following medications: Adderall XR (AMP), atomoxetine (ATMX), and Concerta (MPH-OROS) compared to 95 untreated ADHD patients and 101 NML. Results: Significant differences were detected between normals and untreated ADHD patients. Treated patients performed better than untreated patients but remained significantly impaired compared to normal subjects. Conclusion: Even with optimal treatment, based on parents’ and teachers’ opinions, subtle and not-so-subtle neurocognitive impairments persisted in the ADHD patients. Some ADHD patients may require additional educational assistance, even in the face of successful medication treatment. (J. of Att. Dis. 2007; XX(X) xx-xx)
